Merck KGaA Expands Head and Neck Cancer Therapy Portfolio with Debiopharm’s Xevinapant

By Debadrita Paul & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)

Published: 2 Apr-2021

DOI: 10.3833/pdr.v2021.i4.2603     ISSN: 1756-7874

Section: Licensing



Continuing its interest in the head and neck cancer treatment space, Merck KGaA has agreed to in-license the worldwide rights to Debiopharm’s xevinapant, a potentially first-in-class inhibitor of apoptosis proteins antagonist...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details